

1 Features of patients that died for COVID-19 in a Hospital in the south of Mexico: A  
2 observational cohort study.

3 Jesús Arturo Ruíz-Quiñonez<sup>1#</sup>, Crystell Guadalupe Guzmán-Priego<sup>2#</sup>, German  
4 Alberto Nolasco-Rosales<sup>2</sup>, Carlos Alfonso Tovilla-Zarate<sup>3</sup>, Oscar Israel Flores-  
5 Barrientos<sup>1</sup>, Víctor Narváez-Osorio<sup>1</sup>, Guadalupe del Carmen Baeza-Flores<sup>2</sup>,  
6 Thelma Beatriz Gonzalez-Castro<sup>4</sup>, Carlos Ramón López-Brito<sup>1</sup>, Carlos Alberto  
7 Denis-García<sup>1</sup>, Agustín Pérez-García<sup>1</sup>, Isela Esther Juárez-Rojop<sup>2\*</sup>.

8

9 <sup>1</sup>Hospital de Alta Especialidad Dr. Juan Graham Casasús, Secretaría de Salud,  
10 Villahermosa, Tabasco, México.

11 <sup>2</sup>División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de  
12 Tabasco. Villahermosa, Tabasco, México.

13 <sup>3</sup>División Académica Multidisciplinaria de Comalcalco, Universidad Juárez  
14 Autónoma de Tabasco, Comalcalco, Tabasco, 86650, México.

15 <sup>4</sup>División Académica de Multidisciplinaria de Jalpa de Méndez, Universidad Juárez  
16 Autónoma de Tabasco. Jalpa de Méndez, Tabasco, México.

17

18 Correspondence to: Isela Esther Juárez-Rojop. Av. Gregorio Méndez Magaña, No.  
19 2838-A. Col. Tamulté. C.P. 86300, Villahermosa, Tabasco, México. Email:  
20 iselajuarezrojop@hotmail.com

21 <sup>#</sup>These authors contributed equally to this work.

22

## 23 **Abstract**

24 **Background:** Due to the wide spread of SARS-CoV2 around the world, the risk of  
25 death in individuals with metabolic comorbidities has dangerously increased. Mexico  
26 has a high number of infected individuals and deaths by COVID-19, as well as an  
27 important burden of metabolic diseases. However, reports about features of Mexican  
28 individuals with COVID-19 are scarce. The aim of this study was to evaluate  
29 demographic features, clinical characteristics, and the pharmacological treatment of  
30 individuals who died by COVID-19 in the south of Mexico.

31 **Methods:** We performed an observational study including 185 deceased individuals  
32 with confirmed diagnosis of COVID-19. Data were retrieved from medical records.  
33 Categorical data was expressed as proportions (%) and numerical data were  
34 expressed as mean  $\pm$  standard deviation. Comorbidities and overlapping symptoms  
35 where plotted as Venn diagrams. Drug clusters were plotted as dendrograms.

36 **Results:** The mean age was 59.53 years. There was a male predominance (60.1%).  
37 The mean hospital stay was  $4.75 \pm 4.43$  days. The most frequent symptoms were  
38 dyspnea (88.77%), fever (71.42%) and dry cough (64.28%). Present comorbidities  
39 were diabetes (60.63%), hypertension (59.57%) and obesity (43.61%). The main  
40 drugs used were azithromycin (60.6%), hydroxychloroquine (53.0%) and oseltamivir  
41 (27.3%).

42 **Conclusions:** Mexican individuals who died of COVID-19 had shorter hospital stays,  
43 higher frequency of shortness of breath, and higher prevalence of diabetes

44 compared with individuals from other countries. Also, there was a high frequency of  
45 off-label use of drugs for their treatment.

46 **Key word:** COVID-19; SARS-CoV-2, comorbidities; COVID-19 treatment.

## 47 **Introduction**

48 On December 31, 2019, the World Health Organization (WHO) was informed of  
49 cases of pneumonia of unknown etiology in Wuhan, China. The Chinese authorities  
50 identified a new type of coronavirus, which was isolated on January 7, 2020 (1).  
51 Coronaviruses are enveloped RNA viruses related to SARS (Severe Acute  
52 Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome)  
53 coronaviruses. The novel coronavirus was named SARS-CoV2 and COVID-19 is the  
54 name of the disease it causes (2, 3). Since it was discovered, SARS-CoV-2 has  
55 widely spread around the world; by August 15<sup>th</sup> 2020, there were 21,037,564  
56 confirmed cases and 755,455 deaths reported (4).

57 Up to date, there are some reports and reviews about COVID-19 characteristics in  
58 individuals from a few populations around the world. These reports agree that the  
59 median age of hospitalized individuals is between 47 and 73 years, with a male  
60 predominance (60%). Also, the most common symptoms in hospitalized patients are  
61 fever (90%), dry cough (60 – 86%), shortness of breath (53 – 80%), fatigue (38%),  
62 nausea/vomiting or diarrhea (15 – 39 %), and myalgia (15 – 44%). The most frequent  
63 comorbidities observed in hospitalized individuals included hypertension (48 – 57%),  
64 diabetes (17 – 34%) and cardiovascular diseases (21 – 28%). Comorbidities are

65 more common in hospitalized individuals (60 – 90%) compared with the overall  
66 infected population (25%) (5).

67 In Mexico, the first case of COVID-19 was detected on February 27, 2020 (6);  
68 whereas on August 15<sup>th</sup>, there were 505,751 confirmed cases and 55,293 deaths  
69 (4). Researches suggest that an important burden of metabolic diseases such as  
70 diabetes (10.3%), hypertension (18.4%) and obesity (36.1%) is present in the  
71 Mexican population (7), therefore this population could be highly vulnerable to  
72 COVID-19.

73 Up to today, there are few reports that include epidemiological data to evaluate  
74 comorbidities as risk factors in the Mexican population (8, 9). Additionally, we found  
75 only one report evaluating gastrointestinal symptoms in Mexican patients with  
76 COVID-19 (10).

77 We believe it is important to evaluate which pharmacological treatment are used.  
78 Although there is not directed antiviral therapy recommended against SARS-CoV-2  
79 (11-13), in our sample some off-label drugs were administrated regardless of what  
80 has been observed in clinical trials, particularly at the beginning of the pandemic.  
81 Therefore, our aim was to evaluate demographic features, clinical characteristics,  
82 and pharmacological treatment received by individuals who died by COVID-19 in a  
83 third level hospital in the south of Mexico.

84

## 85 **Methods**

86 This was an observational retrospective study performed at the High Specialty  
87 Regional Hospital “Dr. Juan Graham Casasús” (HJGC) in Villahermosa, Tabasco,  
88 Mexico. We used the medical records of every individual with COVID-19 as the  
89 cause of death, who was admitted to the HJGC from April 15th to May 12th, 2020.  
90 These individuals had been diagnosed with COVID-19 by epidemiologists following  
91 the Mexican Health Secretary’s guidelines; additionally, they tested positive for  
92 SARS-CoV-2 by Reverse Transcriptase Polymerase Chain Reaction. The ethical  
93 approval was granted by the Research Ethics Committee of the Juárez Autonomous  
94 University of Tabasco (103/CIP-DACS/2020) in Mexico.

95 Three physician doctors retrieved data from clinical files after patients’ death. Data  
96 collected included age, gender, clinical symptoms, underlying comorbidities, length  
97 of hospital stay, and drugs used as COVID-19 treatment.

98 We performed a descriptive report. Numerical data was expressed as mean  $\pm$   
99 standard deviation and proportions (%) for categorical data. Gender, age and  
100 comorbidities were compared using the Chi-squared test, with significance of  $p =$   
101 0.05. Comorbidities and overlapping symptoms were plotted as Venn diagrams.  
102 Drug clusters were plotted as dendrograms. All data were analyzed using SPSS  
103 v.23.

104

## 105 **Results.**

106 In this study, the files of 185 deceased individuals were included; these individuals  
107 had been diagnosed and treated for COVID-19 between April 15 and May 12, 2020

108 at the HJGC in Villahermosa Tabasco, Mexico. The length of time in hospital was  
 109 4.75 days in means (S.D. 4.43). The distribution of days of hospitalization by gender  
 110 is shown in Fig 1.

111 **Fig 1. Individuals who died of COVID-19 stratified by gender and days of**  
 112 **hospitalization.**

113

## 114 **Age and Gender**

115 The mean age of the individuals studied was 59.53±12.50 (range 24-86) years.  
 116 When we stratified them by age, the majority of deaths occurred in individuals 65+  
 117 years (36.7%, n=58). Nevertheless, the groups of 55 and 65+ years constituted  
 118 67.7% of the sample (n=107). The comparison between males and females is shown  
 119 in Table 1. No significant differences were observed between groups in terms of age.

120 **Table 1. Characteristics stratified by gender of individuals who died of**  
 121 **COVID-19.**

	All	Male	Female	X <sup>2</sup> , p
Total	158	95 (60.1)	63 (39.9)	
Age				4.36, 0.35
24-34	5 (3.2)	3 (3.2)	2 (3.2)	
35-44	13 (8.2)	9 (9.5)	4 (6.3)	
44-54	33 (20.9)	24 (25.3)	9 (14.3)	
55-64	49 (31.0)	29 (30.5)	20 (31.7)	
65+	58 (36.7)	30 (31.6)	28 (44.4)	
Any comorbidity				2.55, 0.11
Yes	101 (63.9)	56 (58.9)	45 (71.4)	
No or not reported	57 (36.1)	39 (41.1)	18 (28.6)	
Type 2 Diabetes-Yes	56 (35.4)	27 (27.4)	29 (46.0)	1.83, 0.17
Obesity-Yes	41 (25.9)	21 (22.1)	20 (31.7)	5.13, 0.12

Hypertension- Yes	56 (35.4)	31 (32.6)	25 (39.7)	0.82, 0.36
----------------------	-----------	-----------	-----------	------------

122

## 123 **Symptoms**

124 The most common symptoms on admission were shortness of breath (overall:  
125 88.77%; males: 55.2%, females: 44.8%), fever (overall: 71.42%, males: 51.4%,  
126 females: 48.6%), dry cough (overall: 64.28%: males: 58.7%, females: 41.3%),  
127 headache (overall: 43.87%, males: 55.8%, females: 44.2%), and myalgia (overall:  
128 34.69%, males: 44.1%, females: 55.9%). When overlapping symptoms were  
129 observed, the first cluster included fever, dry cough, shortness of breath and  
130 headache. Other cluster was fever, dry cough, shortness of breath, myalgia,  
131 arthralgia and headache. Then fever, dry cough, shortness of breath, myalgia and  
132 arthralgia without headache. And fever and shortness of breath (Fig 2).

133 **Fig 2. Venn diagram of overlapping symptoms.** We plotted overlaps between the  
134 three main symptoms found in the sample. The higher proportions were fever or  
135 cough only, without manifestation of another symptom. The largest overlap was the  
136 triad fever-cough-dyspnea. Then, in order of frequency the main overlaps were  
137 fever-dyspnea and cough-dyspnea.

138

## 139 **Comorbidities**

140 The most common comorbidities on admission were Type 2 Diabetes (60.63%),  
141 hypertension (59.57%) and obesity (43.61%). The main overlap between these

142 comorbidities were T2D-Hypertensión. The second cluster was T2DM-  
143 Hypertension-Obesity and finally Hypertension-Obesity (Fig 3).

144 **Fig 3. Venn diagram of overlapping comorbidities.** The main overlap was the  
145 dyad Hypertension-T2D. The frequency of these comorbidities alone was almost  
146 equal. The next overlaps in order of frequency were the triad Hypertension-T2D-  
147 Obesity and the dyad Hypertension-Obesity.

### 148 **Pharmacological therapy**

149 The most frequent drugs used for treating individuals with COVID-19 were  
150 azithromycin (60.6%) and hydroxychloroquine (53%). Less frequently employed  
151 were oseltamivir (27.3%), tocilizumab (16.77%) and lopinavir-ritonavir (16.7%).  
152 Drugs for various purposes (e.g. paracetamol, dexamethasone) were grouped as  
153 others, these were given to 66.7% of the patients.

154 Clustering drugs. We observed that azithromycin and hydroxychloroquine were  
155 frequently given together, followed by lopinavir-ritonavir with tocilizumab, and  
156 oseltamivir with lopinavir-ritonavir or tocilizumab (Fig 4).

157 **Fig 4. Dendrogram of relationships between drugs used.** The closest relation  
158 was azithromycin – hydroxychloroquine, followed by oseltamivir – lopinavir or  
159 tocilizumab.

160

### 161 **Discussion**

162 In this study, we gathered clinical and demographic characteristics of individuals who  
163 died of COVID-19; we also identified drugs that were most used as antiviral  
164 treatment in those individuals.

165 There were 60% of male individuals. Gender consistency was an expected statistic  
166 as COVID-19 shows male predominance in Mexico's epidemiological data (8), as  
167 well as in other populations (5, 14-16). We found that 67.7% of individuals were  $\geq 55$   
168 years old. Although age varies widely among reports, our results are comparable to  
169 samples from patients with severe COVID-19 (14, 17). The mean length time  
170 hospitalized in days was  $4.75 \pm 4.43$ , which is shorter than what was reported in an  
171 observational study of fatal cases from Wuhan, China ( $6.35 \pm 4.51$ ) (17).

172 Shortness of breath, fever and dry cough were the most prevalent symptoms in our  
173 sample. Fever and cough had been reported as the most prevalent symptoms in  
174 several studies, including the Mexican population and severe cases (5, 10, 15, 17-  
175 19). On the other hand, the third most prevalent symptom varies widely; for instance,  
176 a review found dyspnea prevalence of 53 – 80%, and a series of fatal cases found  
177 in 70.6% (5, 17). Nonetheless, in clinical series and meta-analysis involving non-  
178 lethal cases, the third most prevalent symptom was myalgias or fatigue (31-67%)  
179 (10, 15, 18, 19). In our sample, shortness of breath was the most prevalent symptom  
180 and it was present in every cluster of symptoms, which could indicate that shortness  
181 of breath is an early symptom and bad prognosis.

182 The most common comorbidities in our sample were type 2 diabetes, hypertension  
183 and obesity. Remarkably, diabetes and hypertension had similar frequencies. In  
184 Mexican individuals with COVID-19, it is reported a slightly higher frequency of

185 hypertension compared with diabetes (8, 10). Nonetheless, in other populations  
186 hypertension has a much higher prevalence compared to diabetes (5, 18). In two  
187 meta-analyses from the same work group (20, 21), hypertension and diabetes were  
188 associated with poor outcomes in COVID-19. The hypertension association was  
189 influenced by gender, but not by age or diabetes, while the diabetes association was  
190 influenced by age and hypertension. On the other hand, in a study using  
191 OpenSAFELY database (16), hypertension was associated with an increased risk  
192 (HR 1.09) but it could not be associated when the risk was adjusted to age, gender,  
193 diabetes and obesity. In addition, diabetes and obesity were associated with an  
194 increased risk of death (HR 1.90 and 1.92, respectively). Furthermore,  
195 epidemiological data of COVID-19 in Mexico, indicates that obesity is a risk factor  
196 for death and is a partial mediator on the effects of diabetes in decreased survival  
197 (8). Finally, when comorbidities in our sample were clustered, we observed a lower  
198 frequency of individuals with only-hypertension compared with only-diabetes and  
199 only-obesity patients. Therefore, diabetes and obesity should not be overlooked as  
200 strong risk factors and poor outcomes.

201 In our sample, the most frequent treatment was hydroxychloroquine associated with  
202 azithromycin. Although there is evidence of in vitro activity against SARS-CoV-2, the  
203 use of hydroxychloroquine and azithromycin for clinical benefit is supported by  
204 limited and conflicting clinical data (22). Antiviral agents were next in frequency  
205 order. Oseltamivir was the third most administrated treatment. However, there are  
206 no reports about oseltamivir having in vitro activity against SARS-CoV-2. Although  
207 some clinical trials include oseltamivir, it is not proposed as therapeutic intervention

208 (23). Lopinavir-ritonavir was less frequently used as treatment in our sample; while  
209 it is reported in vitro activity against SARS-CoV-2, clinical trials have failed in  
210 associate it with better clinical outcomes (24). Finally, the only immunomodulatory  
211 drug used in our sample was tocilizumab. In a meta-analysis, tocilizumab was  
212 associated with a significant decrease in mortality rate and ameliorate clinical  
213 symptoms in patients with COVID-19 (25). Despite of its promising results,  
214 immunomodulatory drugs access is limited and it is not broadly used in clinical  
215 settings in Mexico.

216 Our study has some limitations. First, we had limited information about some  
217 individuals because they died within minutes after their arrival to the emergency  
218 room. Second, we did not include surviving individuals so we could not compare  
219 characteristics between groups. Third, we included data of only one frontline hospital  
220 for treating COVID-19. Consequently, this report shows characteristics and handling  
221 of patients at the beginning of the COVID-19 pandemic at the south of Mexico;  
222 therefore, our data cannot be applied to the whole Mexican population.

223 In conclusion, our study showed a high frequency of off-label use of drugs that have  
224 insufficient evidence of their efficacy against COVID-19. The individuals in our  
225 sample had shorter hospital stays, higher frequency of shortness of breath, and  
226 higher prevalence of diabetes compared with similar populations from other  
227 countries. It is important to do more clinical series and cohorts in Mexican population,  
228 as this population shows features that could differ of populations of other countries.

229

## 230 **References**

231

232 1. World Health Organization. Situation Report - 1 [Internet]. Geneva: World  
233 Health Organization; 2020 [updated 01/20/2020; cited 2020 Jul 6]. Available from:  
234 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)  
235 [sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4).

236 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus  
237 from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*.  
238 2020;382(8):727-33.

239 3. World Health Organization. Naming the coronavirus disease (COVID-19) and  
240 the virus that causes it. [Internet]. Geneva: World Health Organization; 2020  
241 [updated 2020 Feb 11; cited 2020 Jul 5]. Available from:  
242 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
243 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
244 [it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it).

245 4. WHO coronavirus disease (COVID-19) dashboard. [Internet]. World Health  
246 Organization. 2020 [cited 2020 Aug 25]. Available from: <https://covid19.who.int/>.

247 5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.  
248 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease  
249 2019 (COVID-19): A Review. *JAMA*. 2020; doi: 10.1001/jama.2020.12839.

250 6. Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E.  
251 Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020.  
252 *Revista Clínica Española*. 2020; doi: 10.1016/j.rce.2020.05.007.

- 253 7. Instituto Nacional de Estadística y Geografía. Encuesta Nacional de Salud y  
254 Nutrición (ENSANUT) 2018 [Internet]. Mexico City: Instituto Nacional de Estadística  
255 y Geografía; 2018 [updated 2020 Apr 20; cited 2020 Jul 14]. Available from:  
256 <https://www.inegi.org.mx/programas/ensanut/2018/default.html#Documentacion>.
- 257 8. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,  
258 González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-  
259 2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in  
260 Mexico. *The Journal of Clinical Endocrinology & Metabolism*. 2020;105(8).
- 261 9. Kammar-García A, Vidal-Mayo JJ, Vera-Zertuche JM, Lazcano-Hernández  
262 M, Vera-López O, Segura-Badilla O, et al. Impact of Comorbidities in Mexican  
263 SARS-CoV-2-Positive Patients: A Restrospective Analysis in a National Cohort.  
264 *Revista de investigacion clinica; organo del Hospital de Enfermedades de la*  
265 *Nutricion*. 2020;72(3):151-8.
- 266 10. Remes-Troche JM, Ramos-de-la-Medina A, Manríquez-Reyes M, Martínez-  
267 Pérez-Maldonado L, Lara EL, Solís-González MA. Initial Gastrointestinal  
268 Manifestations in Patients with SARS-CoV-2 in 112 patients from Veracruz  
269 (Southeastern Mexico). *Gastroenterology*. 2020; doi:  
270 10.1053/j.gastro.2020.05.055:S0016-5085(20)34708-9.
- 271 11. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving  
272 Sepsis Campaign: guidelines on the management of critically ill adults with  
273 Coronavirus Disease 2019 (COVID-19). *Intensive Care Medicine*. 2020;46(5):854-  
274 87.
- 275 12. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-  
276 19) Treatment Guidelines [Internet]. Bethesda: National Institutes of Health; 2020

277 [cited 2020 Jul 26]. Available from:

278 <https://www.covid19treatmentguidelines.nih.gov/>.

279 13. Secretaría de Salud. Recomendaciones para el tratamiento de la infección  
280 por SARS-CoV2, agente causal de COVID-19. [Internet]. Mexico City: Secretaría de  
281 Salud; 2020 [updated 07/06/2020; cited 2020 07/26]. Available from:

282 <https://coronavirus.gob.mx/wp->

283 [content/uploads/2020/07/Recomendaciones\\_para\\_tratamiento\\_SARS-CoV2.pdf](https://coronavirus.gob.mx/wp-content/uploads/2020/07/Recomendaciones_para_tratamiento_SARS-CoV2.pdf).

284 14. Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al. Patients with COVID-19 in 19  
285 ICUs in Wuhan, China: a cross-sectional study. *Critical Care*. 2020;24(1):219.

286 15. Li L-q, Huang T, Wang Y-q, Wang Z-p, Liang Y, Huang T-b, et al. COVID-19  
287 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis.  
288 *Journal of Medical Virology*. 2020;92(6):577-83.

289 16. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.  
290 Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;  
291 doi: 10.1038/s41586-020-2521-4.

292 17. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal  
293 Cases of COVID-19 from Wuhan. A Retrospective Observational Study. *American*  
294 *Journal of Respiratory and Critical Care Medicine*. 2020;201(11):1372-9.

295 18. Tahvildari A, Arbabi M, Farsi Y, Jamshidi P, Hasanzadeh S, Calcagno TM, et  
296 al. Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized  
297 Patients: A Systematic Review of Case Reports and Case Series. *Frontiers in*  
298 *Medicine*. 2020;7:231.

299 19. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL,  
300 et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus

- 301 (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies  
302 from 9 countries. PLOS ONE. 2020;15(6):e0234765.
- 303 20. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased  
304 mortality and severity of disease in COVID-19 pneumonia – A systematic review,  
305 meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical  
306 Research & Reviews. 2020;14(4):395-403.
- 307 21. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is  
308 associated with increased mortality and severity of disease in COVID-19 pneumonia:  
309 A systematic review, meta-analysis and meta-regression. Journal of the Renin-  
310 Angiotensin-Aldosterone System. 2020;21(2):1470320320926899.
- 311 22. Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens  
312 RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review of  
313 the Evidence (or Lack Thereof). Mayo Clinic Proceedings. 2020;95(7):1454-66.
- 314 23. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic  
315 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.  
316 2020;323(18):1824-36.
- 317 24. Kotwani A, Gandra S. Potential pharmacological agents for COVID-19. Indian  
318 J Public Health. 2020;64(6):112-6.
- 319 25. Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et  
320 al. Is there any potential management against COVID-19? A systematic review and  
321 meta-analysis. DARU Journal of Pharmaceutical Sciences. 2020; doi:  
322 10.1007/s40199-020-00367-4.

323